کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3358465 1591753 2016 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Levofloxacin at the usual dosage to treat bone and joint infections: a cohort analysis
ترجمه فارسی عنوان
لووفلوکساسین در دوز معمول برای درمان عفونت استخوان و مفصل: تجزیه و تحلیل کوهورت
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
چکیده انگلیسی


• Recommended dosage for levofloxacin in bone and joint infections is 500 mg once daily for normal weight and renal function.
• Through this recommendation, levofloxacin is associated with low toxicity.
• Through this recommendation, levofloxacin is not associated with a poor prognosis.
• Levofloxacin use in this cohort was consistent with local recommendations.

Fluoroquinolones are recommended for the treatment of bone and joint infections (BJIs), and levofloxacin is commonly used in this setting. However, no pre-marketing clinical study has supported its use, especially its dosage, for treating BJIs. This study aimed to assess the benefit–risk ratio of levofloxacin administered orally at a standard dosage of 500 mg once daily (OD) in a cohort of patients with BJIs. The medical records of patients admitted to a large French teaching hospital for BJI over a 1-year period and managed by a multidisciplinary team were reviewed. Patient data were recorded on a standardised form and the outcome was assessed at the end of antibiotic treatment and after 1-year of follow-up. A total of 230 patients were included, of whom 79 were treated with an antibiotic regimen including levofloxacin (34%). Most BJIs (97%) were surgically treated by wound debridement and/or removal or replacement of the infected device. Adverse drug reactions to levofloxacin leading to treatment discontinuation occurred in three patients (4%). The antibiotic treatment duration was significantly longer in patients treated with levofloxacin compared with other antibiotic regimens (median, 13 weeks vs. 6 weeks). Post-treatment outcomes were considered favourable (total or partial recovery, including orthopaedics aftermath) in 89–93% of patients, with no significant difference between treatment groups. In conclusion, oral levofloxacin at 500 mg OD is a well-tolerated and efficacious antibiotic treatment for BJIs. Our approach of following-up all treated patients is a useful way to validate specific clinical practices.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 47, Issue 6, June 2016, Pages 478–481
نویسندگان
, , , , , , , ,